APOB and cardiovascular disorder: Also, evolocumab Q2W or QM enabled a majority of individuals at high/very-high cardiovascular disease risk to achieve the LDL-C, non-HDL-C, and ApoB goals recommended by the 2019 ESC/EAS dyslipidemia guidelines.